Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06178692
Other study ID # RS1337/20
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date May 10, 2020
Est. completion date May 10, 2024

Study information

Verified date December 2023
Source Regina Elena Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Prospective, multicenter, noninterventional, nonprofit study of a cohort of patients with glioma, aimed at validating miRNA-serum signatures associated with IDH1 status and prognosis, as reliable, specific and sensitive circulating diagnostic biomarkers also useful for improve prognostic stratification of patients. The study will be conducted on serum samples at diagnosis, at 4-6 days postoperatively and/or at the first post-surgery follow-up, in a new cohort of glioma patients and representative of different IDH1 mutational statuses. Furthermore, because comparison of miRNA expression profiles in serum and tissue may provide further evidence to support the use of serum miRNAs as reliable biomarkers reliable, their expression will also be analyzed, where possible, in tissue biopsies from the same patient and compared with the expression profiles of serum miRNAs.


Description:

Scientific data suggest that a serum signature of miRNA could be a promising noninvasive diagnostic and prognostic tool for stratify, by liquid biopsy, patients with glioma according to IDH1 status. It has the primary objective of validating, through non-invasive methods, a signature of Serum miRNAs as reliable, specific and sensitive diagnostic and/or prognostic biomarkers for patients affected by glioma which can also help integrate the molecular analyzes performed on biopsies tissue. The ultimate goal is therefore to validate specific biomarkers for a "medicine" approach personalized" for glioma patients, with potential clinical benefits resulting from improved patient management and identification of the best possible therapy for specific subgroups biological data of patients. Blood samples from cancer patients will be used brain with different IDH1 status and of different grade, recruited from the centers participating in the study. Where possible, tissue samples coming, according to clinical practice, from biopsy will be used to the diagnosis of the same patient. For the analyzes foreseen by the study it will be necessary to take two test tubes (6ml each) with activator of peripheral blood coagulation at diagnosis, at discharge after surgery (4-6 days after surgery) and/or at the first post-surgery check-up. From the serum obtained from blood samples will subsequently be extracted the RNA and the expression level of the miRNAs will be analyzed in individual samples by digital PCR. The method of collection of peripheral blood samples at diagnosis, discharge and/or following the first post-surgery check-up it will be kept uniform throughout study, to minimize preanalytical variables. Any hemolyzed samples will be identified, and excluded from the study, through spectrophotometric analysis and/or by analyzing the level of expression of miR-451, abundant in erythrocytes, and miR-23a, not affected by hemolysis. Where possible, biopsy tissue taken for diagnostic purposes and fixed in formalin and embedded in paraffin (FFPE) will be analyzed for the expression of miRNAs of interest by Real-Time PCR.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 30
Est. completion date May 10, 2024
Est. primary completion date November 17, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - histological diagnosis of glioma; - age=18 years; - No other primary tumor; - No metastatic disease - Informed consent on treatment and molecular analysis Exclusion Criteria: - Histological diagnosis of non-glial tumor; - age< 18; - patients with concomitant other solid tumors - metastatic disease; HIV seropositivity.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Validation of miRNA-serum signatures associated with IDH1 status
Validation of miRNA-serum signatures associated with IDH1 status and prognosis, as reliable, specific and sensitive circulating diagnostic biomarkers also useful to improve prognostic stratification of patients.

Locations

Country Name City State
Italy "Regina Elena" National Cancer Institute Rome

Sponsors (5)

Lead Sponsor Collaborator
Regina Elena Cancer Institute Azienda Ospedaliero Universitaria di Sassari, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Plymouth State University, University of Roma La Sapienza

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Identification of specific forms of circulating microRNAs invasive brain tumors Identification of specific circulating microRNA signatures as non-diagnostic biomarkers invasive brain tumors.
The variables of interest will be summarized by descriptive statistics. ROC curve analysis will be used to evaluate the diagnostic accuracy of miRNAs to be validated. Survival analysis (Overall Survival=OS and Progression Free Survival=PFS) will be conducted through the use of the Kaplan-Meier model and risk regression models Cox proportionals. The log-rank test will be used to test for any differences between groups. The Hazard Risk (HR) and related 95% confidence intervals (95%CI) will be estimated for each variable using univariate and multivariate Cox models. A p value <0.05 will be considered statistically significant. All analyzes will be conducted with SPSS v.21.0 software.
Enlistment period: 6-12 months Total duration of the study: 18-24 months
Secondary Transfer of information in the clinical setting for diagnosis Transfer of this information into the clinical setting for diagnosis, prognosis and purposes therapeutic.
The variables of interest will be summarized by descriptive statistics. ROC curve analysis will be used to evaluate the diagnostic accuracy of miRNAs to be validated. Survival analysis (Overall Survival=OS and Progression Free Survival=PFS) will be conducted through the use of the Kaplan-Meier model and risk regression models Cox proportionals. The log-rank test will be used to test for any differences between groups. The Hazard Risk (HR) and related 95% confidence intervals (95%CI) will be estimated for each variable using univariate and multivariate Cox models. A p value <0.05 will be considered statistically significant. All analyzes will be conducted with SPSS v.21.0 software.
Enlistment period: 6-12 months Total duration of the study: 18-24 months
Secondary Implementation of clinical trials leveraging know-how. Implementation and interpretation of clinical trials using specific know-how generated by the collaborative effort of study participants.
The variables of interest will be summarized by descriptive statistics. ROC curve analysis will be used to evaluate the diagnostic accuracy of miRNAs to be validated. Survival analysis (Overall Survival=OS and Progression Free Survival=PFS) will be conducted through the use of the Kaplan-Meier model and risk regression models Cox proportionals. The log-rank test will be used to test for any differences between groups. The Hazard Risk (HR) and related 95% confidence intervals (95%CI) will be estimated for each variable using univariate and multivariate Cox models. A p value <0.05 will be considered statistically significant. All analyzes will be conducted with SPSS v.21.0 software.
Enlistment period: 6-12 months Total duration of the study: 18-24 months
See also
  Status Clinical Trial Phase
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04681040 - Risk Stratification of COVID-19 Using Urine Biomarkers
Recruiting NCT05372172 - Tennessee Alzheimer's Project
Recruiting NCT06096766 - the Correlation Between Ovarian Function and Serum Biomarkers
Completed NCT04103632 - Screening and Diagnosing Exercise-induced Bronchoconstriction in Recreational Young Athletes (12-18 y) N/A
Completed NCT01159730 - Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers Phase 2
Completed NCT04507724 - The Use of Biochemical Analyzes to Monitor the Development of Wounds
Completed NCT06338111 - Can we Improve Mortality Prediction in Patients With Sepsis in the Emergency Department
Active, not recruiting NCT05027165 - Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
Not yet recruiting NCT02931136 - Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging Phase 4
Not yet recruiting NCT03739892 - Biomarkers to Predict Gain From Therapy in Motor Stroke N/A
Recruiting NCT03801681 - ARrhythmias in MYocarditis
Recruiting NCT05372965 - The Effects of Smoking on miRNA-223 Before-After Non-Surgical Periodontal Therapy in Patients With Stage-3, Grade-B Periodontitis N/A
Completed NCT04772495 - miRNA Biomarkers in Multiple Sclerosis
Recruiting NCT04931537 - Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Recruiting NCT05090410 - Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate Phase 3
Not yet recruiting NCT05764356 - Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II
Recruiting NCT02201446 - The Role of Circulating Soluble CD74 in Acute Lung Injury N/A
Not yet recruiting NCT05752890 - A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma
Completed NCT04786431 - Shotgun Mass Spectrometry-based Lipid Profiling in Chronic Inflammatory Diseases